Lymphogranuloma Venereum Diagnosis and Treatment
Epidemiology and Clinical Presentation
- Lymphogranuloma venereum (LGV) is caused by Chlamydia trachomatis serovars L1, L2, or L3, with L2b and L2 being the predominant strains in recent outbreaks, according to the Centers for Disease Control and Prevention (CDC) 1, 2
- LGV presents in three stages with varying clinical manifestations, including a self-limited genital ulcer at the site of inoculation, tender inguinal and/or femoral lymphadenopathy, and lymphatic obstruction, as reported by the CDC 1, 2
- Women and men who have sex with men (MSM) may develop proctocolitis or inflammatory involvement of perirectal lymphatic tissues, as noted by the CDC 1, 2
- The secondary stage of LGV is characterized by tender inguinal and/or femoral lymphadenopathy, typically unilateral in heterosexuals, according to the CDC 1, 3
Diagnosis and Treatment
- The CDC recommends serological testing, including complement fixation titers ≥64 and microimmunofluorescence (MIF) titers ≥256, to diagnose LGV, with a sensitivity of 80% at 2 weeks 4, 5
- Modern diagnosis relies on nucleic acid amplification tests (NAATs), which can detect C. trachomatis but cannot distinguish between serovars, as reported by the Infectious Diseases Society of America (IDSA) 5
- The recommended treatment for LGV is doxycycline 100 mg orally twice daily for 21 days, according to the CDC 1, 2, 3
- Alternative regimens include erythromycin base 500 mg orally four times a day for 21 days, as recommended by the CDC 1, 3
- Pregnant and lactating women should be treated with erythromycin, as advised by the CDC 3